Loading date...

Saransh Kanaujia

Saransh Kanaujia is a journalist and editor associated with Matribhumi Samachar Group, covering Indian national affairs, business and economy, technology, government policies, and other major developments. His work focuses on providing timely news coverage, explainers and updates for readers in India and abroad.
Editor
Follow:
13050 Articles

Sirios Resources Steps Into the Spotlight at Red Cloud Pre-PDAC with James Bay Gold Expansion Strategy

Montreal, Quebec--(Newsfile Corp. - February 23, 2026) - Sirios Resources (TSXV: SOI)…

Saransh Kanaujia

Renty.ae Expands Luxury Car and Yacht Fleet Following Strong Growth in Bookings

Dubai, United Arab Emirates--(Newsfile Corp. - February 23, 2026) - Renty.ae, a…

Saransh Kanaujia

NioBay Metals to Present Its North American Niobium Strategy at Red Cloud’s Pre-PDAC Showcase

Montreal, Quebec--(Newsfile Corp. - February 23, 2026) - NioBay Metals Inc. (TSXV:…

Saransh Kanaujia

Regal Partners Holdings Pty Limited and Regal Partners Funds Management Pty Limited Sells Shares of Resouro Strategic Metals Inc.

Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Regal Partners Holdings…

Saransh Kanaujia

Critical One Energy Receives Exploration Permit for Howells Lake Antimony-Gold Project

Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - Critical One Energy Inc. (CSE:…

Saransh Kanaujia

AML Incubator Launches Audit-Ready AML Readiness Program for Fintech Firms

The new offering helps teams build evidence trails, monitoring controls, and governance…

Saransh Kanaujia

Peter Czimback Joins CieloVision Advisory Board

Innovation Executive to Help Scale CieloVision's Orchestration Strategy and Differentiate Beyond CMS…

Saransh Kanaujia

Templar Corporate: Invitation to PDAC 2026 Booth 2613

Perth, Western Australia--(Newsfile Corp. - February 23, 2026) - Visit Templar Corporate…

Saransh Kanaujia

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to…

Saransh Kanaujia